13.91USD+2.81%Mkt Cap: 3.03B USDP/E: —Last update: 2026-05-26
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic …
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap3.03B USD
Enterprise Value2.01B USD
Revenue (TTM)10.68M USD
Gross Profit-245.58M USD
Net Income (TTM)-276.48M USD
Revenue/Share0.0610 USD
Last Price13.91 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees193
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.86
PEG—
EV/EBITDA-6.83
EV/Revenue187.95
P/S245.14
P/B4.19
EPS (TTM)-1.56
EPS (Forward)-1.74
52W Range
2.75077% of range17.32
52W High17.32 USD
52W Low2.750 USD
Profitability
Gross Margin0.00%
Oper. Margin-2619.67%
EBITDA Margin0.00%
Profit Margin-1800.58%
ROE-48.76%
ROA-44.50%
Growth
Revenue Growth-60.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-235.46M USD
CapEx (TTM)410.00K USD
FCF Margin-1135.08%
FCF Yield-4.00%
Net Debt-610.50M USD
Net Debt/EBITDA2.08
Balance Sheet
Debt/Equity0.06
Current Ratio22.13
Quick Ratio21.58
Book Value/Sh3.261 USD
Cash/Share3.351 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)22.83 USD
Target Range18.00 USD – 29.00 USD
# Analysts12
Ownership
Shares Out.191.59M
Float128.36M
Insiders1.57%
Institutions92.93%
Short Interest
Short Ratio7.6d
Short % Float17.09%
Short % Out.14.33%
Shares Short27.41M
Short (prev mo.)21.94M
Technical
SMA 5012.73 (+9.3%)
SMA 2008.267 (+68.3%)
Beta1.75
S&P 52W Chg28.31%
Avg Vol (30d)3.93M
Avg Vol (10d)5.33M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—